Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFusion Antibody Share News (FAB)

Share Price Information for Fusion Antibody (FAB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.80
Bid: 3.70
Ask: 3.90
Change: 0.00 (0.00%)
Spread: 0.20 (5.405%)
Open: 3.80
High: 3.80
Low: 3.80
Prev. Close: 3.80
FAB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS: Tan Delta revenue jumps; Kendrick Resources loss widens

Fri, 29th Sep 2023 21:19

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Friday and not separately reported by Alliance News:

----------

Tan Delta Systems PLC - Sheffield, England-based equipment monitoring and data analysis sensors maker - Reports revenue in the six months to June 30 increased by 54% to GBP0.96 million from GBP0.62 million the year prior. Pretax loss totalled GBP298,000 compared to pretax profit of GBP21,000. Basic and diluted loss per share was GBP0.01 against zero last year. Says revenue was primarily driven by a small number of prospects who commenced implementations following their evaluation period, and by a number of small sales to new customers commencing their evaluations. In the second half, expects more customers to enter and commence implementation on their equipment fleets, as well as contribution from our off the shelf SENSE-2 and MOT products.

----------

Oriole Resources PLC - London-based gold exploration company, focused on an early stage exploration project in Cameroon and Senala gold project in Senegal - Reports zero revenue in the six months to June 30, unchanged from the year prior. Administration expenses fell to GBP523,000 from GBP583,000 but pretax loss widened to GBP863,000 from GBP392,000. This reflected an adverse, non-cash foreign exchange loss on overseas assets. Basic loss per share totalled GBP0.03 versus zero the year before.

----------

CAP-XX Ltd - Sydney-based supercapacitor and energy management system manufacturer - Reports revenue in the year to June 30 of AUD3.6 million, down from AUD5.6 million the year prior. Pretax loss widened to GBP5.6 million from GBP4.9 million the year before and basic loss per share totalled 1.1 cents compared to 1.0c. Continues to pursue patent infringement action against Maxwell Technologies and other parties. Notes operating expenses were negatively impacted by AUD1.5 million of associated legal expenditure, down AUD1.0 million on prior year.

----------

Fusion Antibodies PLC - Belfast-based contract research organisation providing discovery, design and optimisation services for therapeutic antibodies to the healthcare market - Reports revenue in the year to March 31 fell 40% to GBP2.9 million from GBP4.8 million the year before, while the pretax loss widened to GBP2.9 million from GBP1.3 million. Basic loss per share totalled 10.0 pence compared to 4.6p. Explains this year has been a tough year and very commercially challenging. The year has seen a downturn in market conditions and investment into customers' early-stage therapeutic pipelines Venture capital funding, typically the primary source of investment for early-stage biotech, has fallen to its lowest level since 2019. Says: "Whilst there remains a significant amount of uncertainty over the timing and implementation of future contract wins due to reduced investment in the broader biotech sector, we expect trading to recover incrementally over the short to medium term both in respect of existing services and the new services coming on stream."

----------

Kendrick Resources PLC - London-based Scandinavia-focused mineral exploration and development company - Reports zero income in the six months to June 30 compared to GBP10,872 the year prior. Pretax loss widened to GBP244,534 from GBP184,700 while basic loss per share totalled 0.10 pence compared to 0.24p. Says review of the company's projects gives confidence that "our north European assets are well located with significant potential in the quickly emerging space of energy generation and storage." Remains confident they have assembled an enviable portfolio of projects and look forward to advancing all projects in the second half of the year and providing shareholders with the prospects of enhanced value flowing into next year.

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
28 Apr 2020 11:19

Fusion Antibodies raises £3m for Covid-19 research

(Sharecast News) - Fusion Antibodies has raised £3m from investors to extend its research to cover potential treatments for Covid-19.

Read more
30 Mar 2020 16:52

Fusion Antibodies Trading In Line With Expectations Amid Outbreak

Fusion Antibodies Trading In Line With Expectations Amid Outbreak

Read more
17 Mar 2020 15:54

DIRECTOR DEALINGS SUMMARY: IWG And Man Chiefs Buy GBP3 Million Worth

DIRECTOR DEALINGS SUMMARY: IWG And Man Chiefs Buy GBP3 Million Worth

Read more
3 Feb 2020 17:32

DIRECTOR DEALINGS SUMMARY: TalkTalk Telecom Boss Buys GBP200,000 Worth

DIRECTOR DEALINGS SUMMARY: TalkTalk Telecom Boss Buys GBP200,000 Worth

Read more
29 Jan 2020 13:35

Fusion Antibodies Expects Annual Revenue Rise Ahead Of Expectations

Fusion Antibodies Expects Annual Revenue Rise Ahead Of Expectations

Read more
29 Jan 2020 09:32

Fusion Antibodies sees 'favourable trends' continue in H2

(Sharecast News) - Pre-clinical therapeutic drug and diagnostics firm Fusion Antibodies said on Wednesday that trading in the third quarter of the financial year had continued the "favourable trends" experienced in the first half.

Read more
10 Jan 2020 12:09

DIRECTOR DEALINGS: Fusion Antibodies Non-Executive Mawson Buys Shares

DIRECTOR DEALINGS: Fusion Antibodies Non-Executive Mawson Buys Shares

Read more
3 Dec 2019 18:08

DIRECTOR DEALINGS: Fusion Antibodies Non-Exec Mawson Buys Shares

DIRECTOR DEALINGS: Fusion Antibodies Non-Exec Mawson Buys Shares

Read more
2 Dec 2019 11:27

Fusion Antibodies cuts losses after revenue leaps

(Sharecast News) - Fusion Antibodies on Monday reported a narrowed loss after revenue more than doubled following the launch of its RAMP service.

Read more
2 Dec 2019 10:49

Fusion Antibodies Revenue Takes Off But Order Visibility Cloudy

Fusion Antibodies Revenue Takes Off But Order Visibility Cloudy

Read more
22 Oct 2019 15:13

Fusion Antibodies pleased with progress in first half

(Sharecast News) - Preclinical antibody discovery company Fusion Antibodies updated the market on the six months ended 30 September on Tuesday, reporting continued revenue growth amid the commercial roll out of new services.

Read more
22 Oct 2019 14:31

Fusion Antibodies Predicts Rise In Interim Revenue And Orders

Fusion Antibodies Predicts Rise In Interim Revenue And Orders

Read more
3 Jul 2019 17:03

DIRECTOR DEALINGS: Fusion Antibodies CEO, Non-Executives Buy Shares

(Alliance News) - Fusion Antibodies PLC said Wednesday that its Chief Executive Officer and two Non-Executive Directors have bought around GBP31,794 in shares in the company in deals on Executive

Read more
2 Jul 2019 10:46

Fusion Antibodies Annual Loss Widens After Rocky First Half

(Alliance News) - Fusion Antibodies PLC on Tuesday said its loss gapped wider after a weak first half brought annual revenue down 19%, though this was followed by a much stronger second antibody a

Read more
17 Apr 2019 11:49

Fusion Antibodies Annual Revenue Declines On Weak First Half

LONDON (Alliance News) - Fusion Antibodies PLC on Wednesday reported an improved performance in the second half of its recently ended financial year after "disappointing" first company a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.